Legal Information
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Application
MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 9 analytes in human serum or plasma samples and tissue/cell lysate and culture supernatants.Analytes included: IFNα-2, IFNβ, IFNε, IFNɣ, IFNɣ Receptor 1, IFNλ1, IFNλ2, IFNλ3, IFNψAssay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Disclaimer
For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
Features and Benefits
Comprehensive Interferon Coverage: Simultaneously quantify all three interferon types (Type I, II, and III) including IFNα-2, IFNβ, IFNε, IFNγ, IFNγ Receptor 1, IFNλ1, IFNλ2, IFNλ3, and IFNψ in a single assay for complete interferon profile analysis.Cost-Effective Sample Utilization: Maximize research efficiency by analyzing multiple interferon biomarkers from minimal sample volumes, reducing sample requirements for serum, plasma, tissue/cell lysate, and culture supernatant studies.Verified Cross-Reactivity Performance: Achieve reliable results with negligible cross-reactivity between antibodies, ensuring accurate quantification of individual interferon analytes for precise inflammation and immunology research.Viral Infection Research: Investigate the first line of defense against viral infections by simultaneously measuring type I and III interferons (IFNα-2, IFNβ, IFNε, IFNλ1, IFNλ2, IFNλ3, IFNψ) involved in antiviral host defense mechanisms.Cancer Immunosurveillance Studies: Analyze interferon-mediated tumor control mechanisms by quantifying IFNγ and interferon receptor expression, supporting malignant cell immunosurveillance research and cancer immunotherapy development.
General description
Interferons (IFNs) are widely expressed cytokines that have potent antiviral and antiproliferative effects. These cytokines are the first line of defense against viral infections and have important roles in immunosurveillance for malignant cells. IFNs are classified as type I, II and III IFNs, based upon the target receptors to which they bind. In humans, type I IFNs belong to a multigene family consisting of multiple IFNα subtypes but only one IFNβ, IFNε, IFNκ, and IFNψ. There is only one type II IFN: IFNγ. The type III IFNs include IFNλ1, λ2 and λ3, which are also known as interleukin-29 (IL-29), IL 28A and IL-28B, respectively. Functionally, the type I and type III IFNs are induced during a viral infection and involved in host defense against viruses. IFNγ (type II) is primarily involved in the allergic response, in host defense against intracellular pathogens, and in control of tumor growth. Studies of IFNs have broadened the mechanistic understanding of cell signaling, gene transcription, and innate and acquired immunity.
